New hope for advanced bile duct cancer patients after standard treatments fail
NCT ID NCT04507503
Summary
This program provides access to the drug futibatinib for patients with advanced bile duct cancer who have a specific genetic change (FGFR2 rearrangement) and whose standard treatments have stopped working or caused too many side effects. The drug is already approved for marketing, so this program helps patients get it before it's widely available. It's for adults who are generally well enough for treatment despite their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32804, United States
-
Aurora Cancer care
Grafton, Wisconsin, 53024, United States
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mount Sinai Center of Florida
Miami Beach, Florida, 33140, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
UCLA Division of Hematology-Oncology
Santa Monica, California, 90404, United States
-
University of California, San Francisco (UCSF)
San Francisco, California, 94143, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Kansas Cancer Center
Lee's Summit, Missouri, 64064, United States
-
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States
Conditions
Explore the condition pages connected to this study.